After hours

West Pharmaceutical Services, Inc.

WST · NYSE

Analyst Consensus

Buy

9 analysts

$413

Current

—

Low

$410

Average

—

High

Average target implies -0.63% versus the current price.

Analyst Ratings Synthesis

Consensus is Buy among 9 analysts, with a reported mean price target of $410. The supplied consensus has no low or high target, so the overall target spread and degree of clustering cannot be established. Among the firm-specific targets in the evidence, TD Cowen’s $500 target is higher than Morgan Stanley’s $400 target. The evidence does not establish a broad revision direction over the past week because the snippets give no action dates. The reported actions show TD Cowen raising its target from $420 to $500 while maintaining Buy, and Morgan Stanley upgrading from Equal-Weight to Overweight and raising its target from $365 to $400. The substantive debate is whether high-value product strength can outweigh West Vantage weakness and SmartDose-related pressures.

Rating Actions

No individual rating actions have been captured for WST yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

CO FORECST

DEUTSCHE BK SEC

JEFFERIES & CO.

KEYBANC CAP MKT

STEPHENS INC

UBS

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: WST
Type: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Country: North America
Exchange: NYSE

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2025 generated $37 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included in the Standard & Poor's 500 index.

Key Issues

Bullish view

Third-quarter results benefited from continued demand for high-value products, including components used in GLP-1 therapies and biologics. Organic sales growth of 11.9% supports the case that demand is translating into broad business momentum.

Bearish view

The supplied evidence does not establish how long strong demand will continue or how much of it comes from GLP-1 therapies. A strong quarter alone does not resolve whether growth can be sustained.

Analyst Consensus

See all

Buy

9 analysts

$413

Current

—

Low

$410

Average

—

High

Average target implies -0.63% versus the current price.

Earnings History

BeatMissNo estimate

West Pharmaceutical Services, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers